Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 3
2004 4
2005 4
2006 3
2007 4
2008 1
2009 8
2010 5
2011 3
2012 6
2013 4
2014 12
2015 13
2016 8
2017 13
2018 12
2019 8
2020 9
2021 11
2022 11
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Results by year

Filters applied: . Clear all
Page 1
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.
Fornecker LM, Lazarovici J, Aurer I, Casasnovas RO, Gac AC, Bonnet C, Bouabdallah K, Feugier P, Specht L, Molina L, Touati M, Borel C, Stamatoullas A, Nicolas-Virelizier E, Pascal L, Lugtenburg P, Di Renzo N, Vander Borght T, Traverse-Glehen A, Dartigues P, Hutchings M, Versari A, Meignan M, Federico M, André M; LYSA-FIL-EORTC Intergroup. Fornecker LM, et al. Among authors: meignan m. J Clin Oncol. 2023 Jan 10;41(2):327-335. doi: 10.1200/JCO.21.01281. Epub 2022 Jul 22. J Clin Oncol. 2023. PMID: 35867960 Free article. Clinical Trial.
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.
André MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, Casasnovas O, Brice P, van der Maazen R, Re A, Edeline V, Fermé C, van Imhoff G, Merli F, Bouabdallah R, Sebban C, Specht L, Stamatoullas A, Delarue R, Fiaccadori V, Bellei M, Raveloarivahy T, Versari A, Hutchings M, Meignan M, Raemaekers J. André MPE, et al. Among authors: meignan m. J Clin Oncol. 2017 Jun 1;35(16):1786-1794. doi: 10.1200/JCO.2016.68.6394. Epub 2017 Mar 14. J Clin Oncol. 2017. PMID: 28291393 Clinical Trial.
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.
Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cheson BD. Barrington SF, et al. Among authors: meignan m. J Clin Oncol. 2014 Sep 20;32(27):3048-58. doi: 10.1200/JCO.2013.53.5229. J Clin Oncol. 2014. PMID: 25113771 Free PMC article.
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).
Bachy E, Camus V, Thieblemont C, Sibon D, Casasnovas RO, Ysebaert L, Damaj G, Guidez S, Pica GM, Kim WS, Lim ST, André M, García-Sancho AM, Penarrubia MJ, Staber PB, Trotman J, Hüttmann A, Stefoni V, Re A, Gaulard P, Delfau-Larue MH, de Leval L, Meignan M, Li J, Morschhauser F, Delarue R. Bachy E, et al. Among authors: meignan m. J Clin Oncol. 2022 Jan 20;40(3):242-251. doi: 10.1200/JCO.21.01815. Epub 2021 Nov 29. J Clin Oncol. 2022. PMID: 34843406 Clinical Trial.
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.
Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Levy R, Newman AM, Dührsen U, Hüttmann A, Meignan M, Casasnovas RO, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA. Kurtz DM, et al. Among authors: meignan m. J Clin Oncol. 2018 Oct 1;36(28):2845-2853. doi: 10.1200/JCO.2018.78.5246. Epub 2018 Aug 20. J Clin Oncol. 2018. PMID: 30125215 Free PMC article.
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D'Aveni-Piney M, Obéric L, Bodet-Milin C, Bories P, Olivier P, Lafon I, Berriolo-Riedinger A, Galli E, Bernard S, Rubio MT, Bossard C, Meignin V, Merlet P, Feugier P, Le Gouill S, Ysebaert L, Casasnovas O, Meignan M, Chevret S, Thieblemont C. Vercellino L, et al. Among authors: meignan m. Blood Adv. 2020 Nov 24;4(22):5607-5615. doi: 10.1182/bloodadvances.2020003001. Blood Adv. 2020. PMID: 33180899 Free PMC article.
Optimizing initial therapy in DLBCL.
Thieblemont C, Bernard S, Meignan M, Molina T. Thieblemont C, et al. Among authors: meignan m. Best Pract Res Clin Haematol. 2018 Sep;31(3):199-208. doi: 10.1016/j.beha.2018.08.001. Epub 2018 Aug 7. Best Pract Res Clin Haematol. 2018. PMID: 30213389 Review.
Deauville score: the Phoenix rising from ashes.
Lopci E, Meignan M. Lopci E, et al. Among authors: meignan m. Eur J Nucl Med Mol Imaging. 2019 May;46(5):1043-1045. doi: 10.1007/s00259-018-4215-9. Epub 2018 Nov 14. Eur J Nucl Med Mol Imaging. 2019. PMID: 30430194 No abstract available.
FDG-PET in PMBCL: which heterogeneity?
Meignan M, Cottereau AS. Meignan M, et al. Blood. 2018 Jul 12;132(2):117-118. doi: 10.1182/blood-2018-05-850305. Blood. 2018. PMID: 30002045 Free article. No abstract available.
126 results